Incyte Corporation’s oral JAK1/2 inhibitor Jakafi (ruxolitinib) has grown to dominate the myelofibrosis market since its approval in 2011. For many years, it was the company’s only commercial asset, and it remains Incyte’s top seller by a wide margin, but it is facing loss of exclusivity (LOE) in 2028. However, while it is under pressure to diversify its revenue base through new products, the company expects to achieve milestones for multiple assets in 2024 that could reach the market ahead of the Jakafi LOE.
Incyte Enters A Data-Rich Year On Path To Portfolio Diversification
Myelofibrosis, Dermatology, Oncology Readouts Ahead
Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.
More from Anticancer
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.